Stepan (SCL) Q3 2026 Earnings Call Transcript

Stepan (SCL) reported Q3 2026 earnings with adjusted EBITDA up 18% YoY to $66.3M, driven by volume growth and margin recovery. Net income rose 64% to $17.8M. Sales increased across surfactants, polymers, and specialty products. Project Catalyst savings exceeded expectations. Management cited geopolitical risks and rising raw material costs as challenges.

Original reporting
Published Oct 28, 2026, 5:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stepan (SCL) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SCLBullishHigh
01

Why it matters

Earnings beat and strong cash generation support a potential share price rally and may prompt analysts to raise targets.

02

Market read

First release of Q3 2026 results, offering fresh data for traders to act on.

03

What to watch

Geopolitical volatility in the Middle East could affect supply chain and cost structure.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Stepan Company is a diversified specialty chemicals producer with three main segments: surfactants, polymers, and specialty products.

Company-level read

Ticker impact

$SCLBullishHigh confidence
Context

Stepan Company reported Q3 2026 earnings with adjusted EBITDA up 18% YoY and net income up 64% YoY.

Expected impact

likely upward pressure as market prices in earnings beat and improved leverage.

Evidence & confidence

Revenue and earnings growth exceed prior expectations; free cash flow and deleveraging actions support a bullish view.

Market effects

Positive for specialty chemicals sector, may lift peers.

U.S. market participants likely to react favorably.

Limited to chemicals and industrial segments.

Counterpoint

Higher raw material costs could compress margins if price discipline wanes.

Key entities

  • Luis E. Rojo

    CEO of Stepan Company, provided commentary on earnings and strategic initiatives.

  • Ruben Velasquez

    CFO of Stepan Company, presented financial metrics during the call.

Related articles

$SCLMed

Stepan Co (SCL) (Q3 2026) Earnings Call Highlights: 7% Organic Volume Growth

Stepan Co (SCL) reported Q3 2026 earnings with 7% organic volume growth and 18% year-over-year adjusted EBITDA increase to $66.3M. Project Catalyst savings exceeded targets, and net leverage improved. Dividends increased for the 59th consecutive year. Challenges include weak polymer volumes in Europe and Asia, rising raw material costs, and a regulatory maintenance turnaround in Germany.

$SCLMedAI 8/10

Stepan Company Q3 2026 Earnings Call Summary

Stepan Company reported Q3 2026 earnings with 7% organic volume growth, driven by North American polymers and surfactants. Margin recovery was sustained through pricing actions and cost offsets. Project Catalyst savings reached $23M quarterly, with expectations to exceed $25M in 2027. The company anticipates full-year 2026 adjusted EBITDA growth, positive free cash flow, and balance sheet deleveraging. Net leverage improved to 2.4x from 2.7x year-over-year.

$SCLMed

Stepan Q3 Earnings Call Highlights

Stepan Company (NYSE: SCL) reported Q3 net sales up 12% to $27M, with adjusted EBITDA rising 5% to $11.7M. Management cited higher volume in MCT products and cost pressures from volatile oil markets. Project Catalyst savings exceeded expectations, with $23M quarterly savings and $66M-$70M expected for 2026. Net debt reduced to $536M, and the dividend was raised by 2.5%.

$SCLMedAI 8/10

Stepan Q3 2026 slides: EPS doubles on volume growth, restructuring

Stepan Company (SCL) reported Q3 2026 adjusted EPS of $0.94, up 98% YoY, driven by 7% volume growth and restructuring savings. Revenue and EPS beat estimates. Shares rose 2.42%. Adjusted EBITDA increased 18% to $66.3M. Project Catalyst restructuring is ahead of schedule, with $23M quarterly savings. Net leverage ratio improved to 2.4x. Free cash flow was $8M, impacted by working capital build.